



# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

*December 21, 2004*

**THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.**

**APPLICATION NUMBER: 60/519,140**

**FILING DATE: *November 12, 2003***

**RELATED PCT APPLICATION NUMBER: *PCT/US04/37813***

Certified by



Jon W Dudas

Acting Under Secretary of Commerce  
for Intellectual Property  
and Acting Director of the U.S.  
Patent and Trademark Office



**BEST AVAILABLE COPY**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**PROVISIONAL APPLICATION FOR PATENT COVER SHEET**

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. ER380175284US

22582 U.S. PTO  
60/519140

111203

INVENTOR(S)					
Given Name (first and middle [if any])		Family Name or Surname		Residence (City and either State or Foreign Country)	
Desuo Walter J.		Wang Sowell		Columbia, SC Columbia, SC	
Additional inventors are being named on the _____ separately numbered sheets attached hereto					
TITLE OF THE INVENTION (500 characters max)					
Compounds for Treating Cardiovascular Conditions and Asthma					
Direct all correspondence to: CORRESPONDENCE ADDRESS					
<input type="checkbox"/> Customer Number		<input type="text"/>		<input type="text"/>	
OR		Type Customer Number here		Place Customer Number Bar Code Label here	
<input checked="" type="checkbox"/> Firm or Individual Name		University of South Carolina			
Address		Osborne Administration Building			
Address		Room 109			
City		Columbia		State	SC
Country		USA		ZIP	29208
		Telephone	803-777-7854	Fax	803-777-9500
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/>	Specification	Number of Pages	38	<input type="checkbox"/>	CD(s), Number
<input type="checkbox"/>	Drawing(s)	Number of Sheets		<input type="checkbox"/>	Other (specify)
<input type="checkbox"/>	Application Data Sheet. See 37 CFR 1.76				
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT					
<input checked="" type="checkbox"/>	Applicant claims small entity status. See 37 CFR 1.27.				FILING FEE AMOUNT (\$)
<input type="checkbox"/>	A check or money order is enclosed to cover the filing fees.				\$80.00
<input type="checkbox"/>	The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: <input type="text"/>				
<input checked="" type="checkbox"/>	Payment by credit card. Form PTO-2038 is attached.				
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input type="checkbox"/>	No.				
<input checked="" type="checkbox"/>	Yes, the name of the U.S. Government agency and the Government contract number are: National Institute of Health 5 K2200367-02				

Respectfully submitted

SIGNATURE

TYPED or PRINTED NAME Walter H. Parham

TELEPHONE 803-777-7854

[Page 1 of 2]

Date 11/12/03

REGISTRATION NO.

(If appropriate)

Docket Number:

341.00.PPA01r2

**USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT**

This collection of information is required by 37 CFR 1.51. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Provisional Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**PROVISIONAL APPLICATION COVER SHEET**  
**Additional Page**

PTO/SB/16 (05-03)

Approved for use through 4/30/2003. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Docket Number	341.02-PPA
---------------	------------

INVENTOR(S)/APPLICANT(S)		
Given Name (first and middle [if any])	Family or Surname	Residence (City and either State or Foreign Country)
Joseph W.	Kosh	Columbia, SC
Ting	Wang	Columbia, SC

[Page 2 of 2]

Number 2 of 2

**WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

**Provisional Patent Application**

**Deseuo Wang, J.W. Sowell, Joseph W. Kosh, and Ting Wang**  
**University of South Carolina**  
**USCRF Invnetion Disclosure #341**

**Compounds for treating cardiovascular conditions and asthma**

**We claim the invention having the embodiments described herein.**

IDF No. (assigned by USCRF):

00341

Disclosure Date (date rec'd by USCRF):

05/20/02

## INVENTION DISCLOSURE FORM

### UNIVERSITY OF SOUTH CAROLINA RESEARCH FOUNDATION

In addition to their significant academic and scientific value, many of the inventions, creations, and/or discoveries made by employees and students of the University of South Carolina (hereinafter the "University") have potential commercial value. Therefore, University policy requires that employees and students disclose all such inventions, creations, and discoveries to the University of South Carolina Research Foundation (hereinafter "USCRF").

This Invention Disclosure Form has been designed to permit University inventors to provide timely and effective notification of their inventions to USCRF. Please fill out each of the sections and attachments as completely as possible.

This disclosure should be considered confidential and proprietary. Please note that early publication, dissemination, or public use of this invention, creation, or discovery may adversely affect the legal protection of your technology.

*NOTE: You must sign the form in Section II, obtain department head and dean/director signatures in Section III, and obtain witness signatures (Section IV) for USCRF to begin to administer your invention or creation, which may include seeking adequate legal protection and exploring licensing and other commercialization opportunities.*

#### SECTION I. Title of Invention and Primary Contact

1. *Non-enabling* title of work: Clinical use of SW0502 compounds to treat cardiovascular conditions (including systemic hypertension, angina pectoris, hypertension-related stroke and heart failure) and spasmodic asthma.

2. Name of contact inventor (who will be speaking and acting on behalf of the inventors listed on page 2):

Desuo Wang

#### SECTION II. Declaration of Ownership, Inventors, Royalty-sharing, and Assignment

For details on disclosures, categories and royalty sharing, see the Intellectual Property Management Office homepage <http://ip.research.sc.edu> or the faculty manual <http://www.sc.edu/policies/facman/research.html>.

1. Please check below to indicate Category of disclosure:

☐

Category 1 - No significant use of University funds, facilities, personnel or other University contribution.

☒

Category 2 - Invention/discovery made with University funding derived from non-University (e.g. - federal, industrial) sources.

☐

Category 3 - Invention/discovery made with University funding from University (e.g. - department, center, foundation) sources.

Note: As used above, University funding includes any funds that flow through the University, USCRF, or any other University-affiliated center or foundation, regardless of origin or funding agency.

2. If Category 2 or 3, I/we agree with the University's standard royalty sharing policy wherein the inventor(s) are entitled to receive 40% of the net licensing income received by the USCRF which is attributed to my/our invention.

☒ Yes

☐ No If no, please explain:

3. Please list below all individuals who will share in the inventors' share of licensing income, if any. Note that with regard to patents, the question of inventorship is a matter of law; failure to list every inventor who contributed to the conception or effective reduction to practice of the invention will invalidate any patent that may issue for this invention. Thus, while being named below entitles one to a share of the inventors' royalties, it does not necessarily ensure that each person listed will be named as an inventor on any patent(s) that may issue. If more than two co-inventors, please use Attachment 1.

As indicated by their signatures below, and subject to the University's policy on intellectual property, the following individuals do hereby:

- A. assign their individual rights and ownership in this invention, creation, or discovery to the University of South Carolina Research Foundation, that the University of South Carolina Research Foundation may, in its sole discretion, administer, protect, license, or otherwise use or exploit this invention for the benefit of the University, USCRF, and the individual inventors; and
- B. agree that their portion of the inventors' share of net income resulting from any licensing, sale, or other commercialization of the invention is to be divided among themselves according to the percentages shown below; and
- C. acknowledge that the abstract provided with this form in Attachment 2 represents a non-enabling description of the technology and may be released, published, or disseminated by the Intellectual Property Management Office in order to attract potential licensing candidates or to assess a potential financial return from this discovery; and
- D. certify that all information provided in this disclosure is true and accurate to the best of their knowledge; and
- E. agree that the individual whose name appears on page 1 of this form in Section I, no. 2, will be the contact point with the Intellectual Property Management Office on behalf of all those listed below. This contact inventor may or may not be the first inventor involved in this discovery; however, he or she should be one of the inventors, and should be listed below as such.

Please print or type:

1. Name: Desuo Wang SSN: 591-86-1245  
Assistant Professor 700 Sumter St.  
Title/position Mailing address  
Basic Pharmaceutical Sciences, College of Pharmacy  
Dept/College  
Inventor's share: 60 (%) Columbia, SC 29208  
City, State, Zip  
Desuo Wang Office phone: 803-777-7101  
Signature Office fax: 803-777-8356  
05-06-02 Email: wang@cop.sc.edu  
Date
2. Name: J. Walter Sowell, Sr. SSN: 436-62-7314  
Professor 700 Sumter St.  
Title/position Mailing address  
Basic Pharmaceutical Sciences, College of Pharmacy  
Dept/College  
Inventor's share: 25 (%) Columbia, SC 29208  
City, State, Zip  
J. Walter Sowell Office phone: 803-777-7916  
Signature Office fax: 803-777-8356  
05/06/2002 Email: sowell@cop.sc.edu  
Date

Note: If there are more than 2 inventors, please use Attachment 1.

### SECTION III. Notifications

The following individuals must sign this Invention Disclosure Form before USCRF can formally begin to administer this invention.

#### Department Head

Joseph W Kosh  
Signature

May 4, 2002  
Date

Name (please print): Joseph W. Kosh

Department: Basic Pharmaceutical Sciences

College/Institute: College of Pharmacy

#### Dean/Director

Farid Sadik  
Signature

5/6/02  
Date

Name (please print): Farid Sadik

College/Institute: College of Pharmacy

### SECTION IV. Witnesses.

*Two witnesses (not co-inventors of the invention) must sign this form. They should be individuals who can attest to the authorship of the invention, are familiar with the history of the invention, and understand the principles involved in the invention. The Department Head and/or Dean may serve as witnesses if they meet the witness criteria.*

1. Name of first witness: James M. Chapman  
Title/position: Associate Professor  
Telephone: 803-777-7926  
USC Department/College OR Basic Pharmaceutical Sciences  
Non-USC employee mailing address: \_\_\_\_\_  
City, State, and Zip: Columbia, SC 29208

James M. Chapman, Jr.  
Farid Sadik  
Signature of Witness

5/7/02  
5/6/02  
Date

2. Name of second witness: Farid Sadik  
Title/position: Dean/Professor  
Telephone: 803-777-4151  
USC Department/College OR College of Pharmacy  
Non-USC employee mailing address: \_\_\_\_\_  
City, State, and Zip: Columbia, SC 29208

Please return this completed form to: Invention Disclosures  
University of South Carolina Research Foundation  
514 Byrnes Building  
Columbia, SC 29208

If you have any questions, please call (803) 777-4031 or (803) 777-9515.

Abbreviated title: Clinical use of SW0502 Primary contact: Desuo Wang, Ph.D.

Attachment 1

Additional Inventors

1. Name: Joseph W. Kosh SSN: 462-60-4820  
Professor 700 Sumter St.  
Title/position Mailing address  
Basic Pharmaceutical Sciences, College of Pharmacy  
Dept/College  
Inventor's share: 10 (%)  
Columbia, SC 29208  
City, State, Zip  
Office phone: 803-777-3465  
Office fax: 803-777-8356  
Email: kosh@cop.sc.edu  
Joseph W Kosh  
Signature  
May 6, 2002  
Date
2. Name: Ting Wang SSN: 657-10-7137  
Graduate Assistant 700 Sumter. St.  
Title/position Mailing address  
Basic Pharmaceutical Sciences, College of Pharmacy  
Dept/College  
Inventor's share: 5 (%)  
Columbia, SC 29208  
City, State, Zip  
Office phone: 803-576-6300  
Office fax: 803-777-8356  
Email: ting@cop.sc.edu  
Ting Wang  
Signature  
05/10/02  
Date

Copy and attach this page as needed for additional inventors.



Abbreviated title: Clinical use of SW0520

Primary contact Desuo Wang, Ph.D.

## Attachment 2

## Description of Invention

1. Please attach a *non-enabling* abstract of the work in *layman's terms*, including practical uses for the work. This abstract should be worded so that an expert in the field would *not* be able to reproduce the invention.

2. Conception date: February 1, 2002 and place: CLS 611, College of Pharmacy, USC

Laboratory notebook or other documentation available? Yes ☐ No ☒ \_\_\_\_\_  
(If No, what proof of inventorship can you provide?)

3. Please attach a complete description of the invention/creation/discovery, including potential industrial applications. Feel free to attach papers, presentations, etc. that describe the technology.

See attachment

4. Describe why the invention is better or more advantageous than present state-of-the-art technology. What benefits does it provide? What problems does it solve? (Attach papers/presentations/abstracts that address these questions.)  
The responses elicited by SW0502 compounds are faster and stronger than that induced by commonly used antihypertensive drugs like beta-adrenergic blockers or calcium channel blockers, but slower and weaker than that caused by nitroglycerin. The compound reduces heart rate and myocardium contraction markedly less than beta-adrenergic blockers and calcium channel blockers. These pharmacological properties craft SW0502 the saver and better choice in treatment of hypertensive condition, hypertension-related stroke and heart failure. The ability of relaxation of bronchial smooth muscles indicates that the compounds can be used to treat patients with spasmodic asthma, especially, in asthma patients who also have high blood pressure. The effectiveness when applied intravenously and orally ensures the feasibility of using the compounds to treat either hypertensive crises or sustained hypertensive conditions. In addition, the relatively low cost of the SW0502 compounds will make SW0502 a better choice in clinical practice.

5. List up to ten (10) key words that help describe or that relate to the work:  
2-diethylaminoacetamido-3-carbamyl-4-methylpyrroles, lidocaine analogs, local anesthetic, antiarrhythmic, vasodepressor, antihypertensive, angina pectoris, stroke, heart failure, spasmodic asthma.

6. Have products, apparatus, or compositions, etc. actually been made? Tested? Is there a prototype? How would you describe the present state of development?

The products have been made and preliminary tests have been performed. There is a prototype of compounds we are working with.

Currently we are 1) modifying the structure of the parent compound to identify the optimal chemical agent that has the maximal therapeutic benefits and causes minimum adverse events; 2) investigating the mechanism(s) that underlie the pharmaceutical effects of SW0502 compounds.

7. Is a company(ies) ready to license the invention? Yes ☐ No ☒

If yes, please list the company(ies) name(s), contact person(s), address(es), and phone number(s).

8. Please list all companies you believe are/may be/should be interested in your discovery. Please list individual contacts at each of these companies, if available, with addresses and phone numbers.

Companies potentially interested in our discovery:

CV Therapeutics

Eli Lilly and Company

Novartis

Merck & Co.

AstraZeneca

Chugai Biopharmaceuticals, Inc.

COR Therapeutics

Abbreviated title: Clinical use of SW0502 compounds Primary contact: Desuo Wang, Ph.D.

### Attachment 3

### Public Disclosures

1. Has the invention been described or discussed in any journal, abstract, paper, oral presentation, news story, thesis, dissertation or other medium? Yes ☐ No ☒

If yes, date \_\_\_\_\_, medium (journal, conference, etc.): \_\_\_\_\_

Name of journal, conference, etc.: \_\_\_\_\_

*Attach copy of abstract, presentation, thesis/ dissertation, etc.*

2. Has there been any past public use, sale, or offer for sale of the invention? Yes ☐ No ☒

If yes, date: \_\_\_\_\_, describe circumstances, including contact person(s), etc. below:

3. Planned publication or other disclosure? Yes ☒ No ☐

If yes, date: May 1, 2004, medium (journal, conference, etc.): Journal and Conference

Name of journal, conference, etc.: Circulation; Circulation Research; Scientific Conference of American Heart Association.

*Attach copy of abstract, presentation, thesis/ dissertation, etc.*

4. Has the invention been disclosed to industry representatives? Yes ☐ No ☒

If yes, date \_\_\_\_\_, describe circumstances, including contact person(s), etc. below:

5. Any other disclosures of the invention/creation? If so, please explain:  
none

Abbreviated title: Clinical use of SW0502 compounds

Primary contact: Desuo Wang, Ph.D.

## Attachment 4 Research Funding, Sponsorship, and Support Information

List *all* of the funding agencies, companies, organizations and sponsors of the research that led to this discovery or invention, including those who supplied materials under a formal materials transfer agreement (MTA) prior to invention or reduction to practice. If none, so state. If more space required, copy this page or attach additional pages as needed.

Name of sponsor (agency/foundation/company/etc.)	<u>NIEHS/NIH</u>
Sponsor's grant/project number	<u>5 K2200367-02</u>
USCRF, SPAR, or USC Foundation account number	<u>11110-FA01</u>
Principal investigator	<u>Desuo Wang</u>
Grant/contract/project title	<u>Effects of Dioxins (TCDD) on Cardiac Ion Channels</u>

Name of sponsor (agency/foundation/company/etc.)	<u></u>
Sponsor's grant/project number	<u></u>
USCRF, SPAR, or USC Foundation account number	<u></u>
Principal investigator	<u></u>
Grant/contract/project title	<u></u>

Name of materials provider, if any	<u></u>
USCRF/USC MTA number	<u></u>
Related research agreement number, if any	<u></u>
Related grant/contract/project title, if any	<u></u>

What University support has this invention or discovery received?

Facilities:	<u>yes</u>
Funding:	<u>no</u>
Services:	<u>no</u>
Other support (e.g., release time, paid technical assistance, etc):	<u>no</u>

Are/were there any other sources of support for this invention or discovery? If so, please explain:  
no

**Clinical use of SW0502 compounds to treat cardiovascular conditions  
(including systemic hypertension, angina pectoris, hypertension-related  
stroke and heart failure) and spasmodic asthma**

Desuo Wang, J. Walter Sowell, Joseph W. Kosh, Ting Wang

May 6, 2002

**Abstract**

We have discovered a group of chemical compounds (SW0502 family) that can markedly relax high potassium-induced contracture (static muscle shortening) of artery (rat and pig), vein (pig), and bronchial (rat) smooth muscles. In whole animal studies of SD rats, the leading compound reduces the blood pressure when it was administered intravenously or via oral gavage at concentrations of 1-20 mg/kg body weight. The depressing effects on smooth muscle contracture and blood pressure are concentration-dependant and reversible upon removal of the compound. The compound-elicited responses are faster and stronger than that induced by commonly used antihypertensive drugs like  $\beta$ -adrenergic blockers or calcium channel blockers, but slower and weaker than that caused by nitroglycerin. The compound reduces heart rate and myocardium contraction markedly less than  $\beta$ -adrenergic blockers and calcium channel blockers. Based on these observations, we claim the sole right to use these compounds in treatment of cardiovascular conditions (including systemic hypertension, angina pectoris, hypertension-related stroke and heart failure) and spasmodic asthma.

## Summary of Invention Disclosure

### CONTACT:

**Desuo Wang, Ph.D. & M.D. (Inventor)**  
**College of Pharmacy**  
**University of South Carolina**  
**700 Sumter St.**  
**Columbia, SC 29208 (USA)**  
**Tel: 803-777-7101**  
**Fax: 803-777-8356**  
**Email: wang@cop.sc.edu**

### OR

**Anthony M. Boccanfuso, Ph.D.**  
**Managing Director**  
**University of South Carolina Research Foundation**  
**Room 501, Byrnes Building**  
**Columbia, SC 29208**  
**Tel: 803-777-4305**  
**Fax: 803-777-4136**  
**Email: amb@sc.edu**

**Compounds to treat cardiovascular conditions (including systemic hypertension, angina pectoris, hypertension-related stroke and heart failure) and spasmodic asthma**

**Abstract**

A group of compounds has been discovered to be effective for the treatment of cardiovascular conditions (including systemic hypertension, angina pectoris, hypertension-related stroke and heart failure) and spasmodic asthma. Testing of the compounds has shown that they can markedly relax high potassium-induced contracture (static muscle shortening) of artery (tested in rat and pig), vein (tested in pig), and bronchial (tested in rat) smooth muscles. In whole animal studies of SD rats, the leading compound reduces the blood pressure when it was administered intravenously (1 mg/kg body weight) or *via* oral gavage (20 mg/kg body weight). The depressing effects on smooth muscle contracture and blood pressure are concentration-dependant and reversible upon removal of the compound. The compound-elicited responses are faster and stronger than that induced by commonly used antihypertensive drugs like  $\beta$ -adrenergic blockers or calcium channel blockers, but slower and weaker than that caused by nitroglycerin. The compound does not reduce heart rate and myocardium contraction as markedly as  $\beta$ -adrenergic blockers and calcium channel blockers.

**Potential Areas of Use**

The treatment of cardiovascular conditions (including systemic hypertension, angina pectoris, hypertension-related stroke and heart failure) and spasmodic asthma.

**Main Advantages**

Responses are faster and stronger than commonly used antihypertensive drugs.  
Less adverse effects (less inhibition on heart rate and myocardium contraction).  
Reduced therapy cost.

**Development Status**

Compound synthesis has been completed.  
Preliminary data have been collected in both tissue and whole animal levels.  
Experiments have been designed to investigate the underlying mechanism(s) of action.

**Demonstration/Validation Status**

In-vitro testing on artery, vein, and bronchial smooth muscles from rats and pigs.  
In Langendorff-perfused isolated rat heart, testing on left ventricular developing pressure (a measurement of myocardial contractility) and coronary flow-rate.  
In-vivo testing on carotid arterial blood pressure and electrocardiogram following intravenous bolus injection and oral gavage administration.

**Future Development Plan**

Toxicity of the compound will be studied.  
Pharmacokinetics (uptake, distribution, binding, metabolism, and elimination) will be studied.  
Experiments will be implemented to investigate the underlying mechanism(s) of action.  
Clinical trial bases have been established.

## Introduction

Hypertension is the most common cardiovascular disease and the management of hypertension is the leading indication for both visits to physicians and the use of prescription drugs in the United States. The elevated blood pressure is closely associated with high morbidity, disability, and mortality from coronary heart disease and strokes. Although antihypertensive therapy can effectively prevent the hemorrhagic strokes, cardiac failure, and renal insufficiency due to high blood pressure, epidemiological studies demonstrate that only 27 percent of hypertensives had their blood pressure well controlled.<sup>1-4</sup> These facts lead the discovery of new antihypertensive agents remains one of the major focuses of R&D of cardiovascular research.

The clinical treatment of hypertension is to prevent the cardiovascular complications that are known to accompany the high blood pressure.<sup>5</sup> Currently, five major classes of drugs are used to lower blood pressure, which include diuretics, adrenergic inhibitors,  $\text{Ca}^{2+}$ -channel blockers, renin-angiotensin inhibitors, and vasodilators.<sup>6</sup> The later, together with  $\text{Ca}^{2+}$  antagonists and angiotensin inhibitors, is becoming wider and earlier choice as first or second line of drugs to control blood pressure.<sup>5</sup>

We have discovered a group of chemical compounds that potently relax vascular and bronchial smooth muscles contracted by high potassium in vitro and lowered the blood pressure in vivo. We, therefore, claim that these compounds have great potential to be developed into new therapeutic agents to treat hypertension and hypertension-related heart diseases and stroke as well as spasmodic asthma.

Chemistry of the Compounds: Omitted.

## Biological Evaluation

### I. Smooth muscle relaxation

#### A. In vitro vascular smooth muscle responses:

The prototype of the compounds was tested for activity to relax vascular smooth muscles using abdominal aorta and vein preparations from Sprague-Dawley rats and Sus-Scrofa pigs. The rat vessels were obtained immediately after the animal was sacrificed for another research project (Animal protocol # 1091, approved by IACUC of University of South Carolina) and the porcine tissues were obtained within 30 min after the pig was sacrificed at the end of an Advanced Trauma Life Support Course (a training course organized by the College of Medicine and Animal Facility of USC). The vessels were cleaned of adherent fat and connective tissue and then cut into 3~5-mm ring segments. The segments were cut longitudinally into arterial strips without removal of the endothelium.

The strips were tied to the extremities by two silk threads and vertically mounted in a water-jacketed tissue bath, maintained at 37 °C, between moveable and fixed ends of a stainless steel wire with the moveable end attached to a TRI 201 isometric transducer (LSi LETICA Scientific Instruments) that was coupled to a bridge amplifier (PowerLab, ADInstruments) for recording isometric force responses. The data were digitized through a 16 SP interface and acquired on-line with Chart 4.1.2 software (PowerLab, ADInstruments) and stored to a personal computer.

The bath was filled with 30 ml of oxygenated (95%  $\text{O}_2$  and 5%  $\text{CO}_2$ ) Krebs's solution containing (in mM): 135 NaCl, 15  $\text{NaHCO}_3$ , 5.4 KCl, 1.2  $\text{NaH}_2\text{PO}_4$ , 1.2  $\text{MgSO}_4$ , 1.8  $\text{CaCl}_2$ , and 10 glucose. The strips were equilibrated for at least 30 min before approximately 0.3 gram (for rat tissues) or 1 gram (for pig tissues) of passive tension was placed on them. Thereafter, contracture (static



muscle shortening) was produced with potassium chloride by substituting 64.6 mM KCl for the same amount of NaCl in the Krebs solution (i.e., final concentration of  $K^+ = 70$  mM). When the potassium-induced contracture reached a stable plateau level, various concentrations of the testing compound were added to the bath solution to record the concentration-response curve. Each concentration of the compound was allowed to elicit its maximal relaxation. In most of the experiments, the higher concentration was reached by accumulatively adding the agent to the bath solution. The relaxation response produced by the compound was normalized to the response produced by 10  $\mu$ M nitroglycerin added to the bath solution at the end of the experiment. Figure 1 shows the typical vascular relaxation effects produced by the prototype of the compounds on rat arterial (panel *a*) and porcine vein (panel *b*) strips.




Figure 1. Prototype compound-produced relaxation of vascular smooth muscles. Panel a. rat abdominal arterial strip was statically shortened by 70 mM KCl indicated by the arrow. The test compound was added accumulatively at the concentration indicated by the numbers. NG=10  $\mu$ M nitroglycerin. Panel b. similar experiment as in Panel a, except that porcine vein strip was used.

#### B. In vitro bronchial smooth muscle responses:

The prototype of the compounds was also tested for activity to relax bronchial smooth muscles using the main bronchi from Sprague-Dawley rats. The rat bronchial tissues were obtained immediately after the rat was sacrificed for another research project (Animal protocol # 1091, approved by IACUC of USC). Both the right and left main bronchi were cleaned of adherent fat and connective tissue and trimmed into ~3 mm ring segments, which were cut longitudinally at the

circumference of the hyaline cartilage without removal of the epithelium. The strips, with the membranous wall (a fibrous membrane containing smooth muscular fibers) in the middle, were tied to the extremities (cartilage+annular ligament) by two silk threads and vertically mounted in a water-jacketed 37 °C tissue bath. The experimental protocol and data acquisition were same as that used for vascular smooth muscles (see above). Figure 2 shows the typical bronchial responses produced by the compound.




Figure 2. The prototype compound-produced relaxation of rat bronchial strip that was statically shortened by 70 mM KCl as indicated by the arrow. The bars and numbers indicate the application time and concentrations of the agent, respectively.

## II. In vivo blood pressure reduction effects

### A. Intravenous bolus injection of the compound on blood pressure:

Female Sprague-Dawley rats weighing 200-225 grams were anesthetized with pentobarbital (30 mg/kg body weight, i.p.). The animal was positioned supinely on a heat plate that was controlled by an automatic temperature controller system (TC-324B, Warner Instrument Corp.) to maintain its body temperature constant (36±0.5°C) during the experiment. The trachea, right carotid artery, and left femoral vein were exposed. The trachea was cannulated and the animal was breathed with air through a respirator at a rate of 65-70/min and an inspiration pressure of ~10 cm H<sub>2</sub>O. PE catheters were implanted into the carotid artery and femoral vein, respectively. The animal was heparinized by i.v. injection of ~300 units of heparin dissolved in 0.3 ml of 0.9% saline. Arterial pressure was recorded from the carotid artery catheter connected to a physiological pressure transducer (SP 844, Capto company, Norway) that was coupled to a bridge amplifier (PowerLab, ADInstruments). The data were digitized through a 16 SP interface and acquired on-line with Chart 4.1.2 software (PowerLab, ADInstruments) and stored to a personal computer.

After surgery, the animal was allowed to equilibrate for ~30 minutes before administration of the test compounds. The experiments in which the control carotid pulse pressure (difference between the systolic and diastolic pressure) was less than 30 mmHg were discarded without testing the drug's effects. Various doses (0.1-4 mg/kg.bw) of the test agents dissolved in 0.9% saline were administered as boluses through the femoral vein cannula in volumes ranging from 0.25-0.3 ml. Same volume of saline was used to flush the injection line following each administration of drug. Each dose of the compound was allowed to elicit its maximal effects. The changes in systolic, diastolic, and mean

pressure (calculated as diastolic pressure + 1/3 pulse pressure) caused by the test agents were compared to that measured at the end of the 30 min equilibration. During the experimental period, ECG was simultaneously recorded with a Bio Amplifier (PowerLab, ADInstruments) through two electrodes placed on the right and left forearms to monitor the possible effect of the test agents on heart rate. Figure 3 shows the representative responses of blood pressure and heart rate after bolus injection of the compound (note: the data shown in figure 3 were from the same rat. The lower mean blood pressure (MBP) and heart rate at the beginning of the recordings in Panel C were due to application of verapamil and nitroglycerin before lidocaine injection).




Figure 3. Effects of the prototype compound on rat carotid blood pressure and heart rate when administered intravenously (bolus injection, Panel a and b). Lidocaine's effects was included for comparison (Panel c). [The experiments were performed in the same rat. Lidocaine's effects were tested after administration of verapamil and nitroglycerin.]

**B. Oral administration of the compound II on blood pressure:**

The prototype of the compounds was administered to two female rats via oral gavage at a dose of 25 and 80 mg/kg.bw, respectively. The agent was dissolved in 0.9% saline in a volume of 0.5 ml. The same volume of saline alone was administered to two control animals. After 15 minutes, the animal was anesthetized with pentobarbital (30 mg/kg.bw, i.p.) and same surgery was performed except that the femoral vein was not exposed and there was no i.v. administration of the test agent. The carotid blood pressure and heart rate were monitored and recorded for 60 minutes using the same method described above. The initial recording was made within 45 to 65 minutes after performing oral gavage. The results are reported in the following Table (the MBP and HR were measured within 30 min after the surgery).

Oral gavage compound on rat blood pressure and heart rate			
	Saline	Compound	
		25 mg/kg.bw	80 mg/kg.bw
MBP (mm Hg)	186	156	126
HR (beat/min)	364	384	300

MBP: mean blood pressure: HR: heart rate

**Reference**

1. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1997; 157:2413
2. Andersson OK, et al. Survival in treated hypertension: Follow up study after two decades. BJM 1998; 317:167-171
3. Woodwell DA: National Ambulatory Medical Care Survey: 1997 Summary. Advance Data from Vital and Health Statistics. 1999; National Center for Health Statistics. Hyattsville, MD; No. 305
4. MacMahon S, et al. Blood pressure and coronary heart disease: Part 1, prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335:765
5. Braunwald E, Zipes DP, Libby P. Heart Disease. A textbook of cardiovascular medicine. (6<sup>th</sup> ed) W.B. Saunders Company. 2001; Vol 1, pp 972-995
6. Oates JA and Brown NJ. Antihypertensive agents and the drug therapy of hypertension. In Goodman & Gilman's The Pharmacological Basis of Therapeutics (10<sup>th</sup> Ed). Publisher: McGraw Hill; 2001; Chapter 33, pp 871-900

**Ligand Pharmaceuticals** - develops drugs in the areas of cancer, skin diseases, and men's and women's hormone related diseases, as well as osteoporosis, metabolic disorders, and cardiovascular and inflammatory diseases.

**Investors@Ligand.com**

Ligand Pharmaceuticals  
10275 Science Center Drive  
San Diego, CA 92121

**Byk Gulden** - specializing in products for gastrointestinal, cardiovascular, respiratory tract diseases, and contrast agents.

**info@byk.ca**

Address: Byk Canada Inc.  
1275 North Service Rd. W.  
Oakville, ON L6M 3G4  
Phone: 905-469-9333  
Toll Free: 1-888-367-3331

**3M Pharmaceuticals Division** - prescription medicines for respiratory, cardiovascular, and immune system, and drug delivery systems for the health care market.

**Mary Zweber**, Director, Business Development, Pharmaceuticals Division

3M Center  
Building 275-3E-07  
St. Paul, MN 55144-1000  
(651) 736-6073 (Direct Line)  
(651) 737-4556 (FAX)

**DexGen Pharmaceuticals, Inc.™**

developing new uses for existing prescription and OTC products, especially in the areas of cardiovascular disease, oncology, and neurology.

PO Box 675

Manasquan, New Jersey 08736

**CustomerService@DexGen.com**

Toll free in the USA and Canada

**1-877-DEXGEN1**

Tel: (732) 223-8811

Fax: (732) 528-4763

地址：中国 浙江 临海市汛桥开发区

produces pharmaceutical raw materials and intermediates in the area of cardiovascular. Products include Captopril, Enalapril Maleate, and Lisinopril.

Xunqiao, Linhai, Zhejiang, China.

电话：0576-5991125 5991126

传真：0576-5991062

邮编：317024

E-mail: **hhphar@mail.tzptt.zj.cn**

**Chugai Biopharmaceuticals**

develops therapeutic agents for the treatment of cardiovascular diseases and cancer.

General Info: **info@chugaibio.com**

Telephone: 858.535.5900

Fax: 858.535.5973

6275 Nancy Ridge Drive, San Diego, CA 92121

Novartis Corporation Novartis' product for hypertension  
Kamran Tavangar, Ph.D.  
Head of Investor Relations North - America  
Tel.: +1 212 830 24 33  
E-mail: [kamran.tavangar@group.novartis.com](mailto:kamran.tavangar@group.novartis.com)  
608 Fifth Ave.  
New York, NY 10020

Fujisawa Healthcare, Inc. is the resource you can trust to bring you the broadest variety of quality pharmaceuticals and related devices. In addition to offering an extensive product line, Fujisawa Healthcare offers a comprehensive list of programs and services that focus on the way you do business.

Public Relations  
Maribeth Landwehr  
Phone: 847-317-8988 Fax: 847-317-7288  
E-mail: [Maribeth\\_Landwehr@fujisawa.com](mailto:Maribeth_Landwehr@fujisawa.com)

Eli Lilly and Company  
Lilly Corporate Center  
Indianapolis, Indiana 46285 USA  
Phone: +1-317-276-2000

Nissan Chemical Industries, Ltd., a revolutionary antihypertension agent offering outstanding results with a high degree of safety due to its long-term and mild effects.  
7-1, Kanda Nishiki-cho 3 chome, Chiyoda-ku, Tokyo 101-0054  
Tel: 03-3296-8320  
Fax: 03-3296-8210  
E-mail: [info@nissanchem.co.jp](mailto:info@nissanchem.co.jp)

**Claes Wilhelmsson** - Executive Director of Research & Development  
AstraZeneca Latin America Inc.  
800 Douglas Road, Suite 750  
Coral Gables, FL 33134  
Tel: +1 305 442 1127  
Fax: +1 305 442 1147  
[partners@astrazeneca.com](mailto:partners@astrazeneca.com)  
or  
AstraZeneca LP  
725 Chesterbrook Blvd.  
Wayne, PA 19087  
Tel: +1 610 695 1000  
Fax: +1 610 889 1280  
[partners@astrazeneca.com](mailto:partners@astrazeneca.com) (contacted on May 28, 2002)

**[CONFIDENTIAL]**

## Summary of Invention Disclosure

May 17, 2002

**DEUO WANG\*, J. WALTER SOWELL,  
JOSEPH W. KOSH, TING WANG**

**\*Contact inventor**

## Introduction


Hypertension is the most common cardiovascular disease and the management of hypertension is the leading indication for both visits to physicians and the use of prescription drugs in the United States. The elevated blood pressure is closely associated with high morbidity, disability, and mortality from coronary heart disease and strokes. Although antihypertensive therapy can effectively prevent the hemorrhagic strokes, cardiac failure, and renal insufficiency due to high blood pressure, epidemiological studies demonstrate that only 27 percent of hypertensives had their blood pressure well controlled.<sup>1-4</sup> These facts lead the discovery of new antihypertensive agents remains one of the major focuses of R&D of cardiovascular research.

The clinical treatment of hypertension is to prevent the cardiovascular complications that are known to accompany the high blood pressure.<sup>5</sup> Currently, five major classes of drugs are used to lower blood pressure, which include diuretics, adrenergic inhibitors,  $\text{Ca}^{2+}$ -channel blockers, renin-angiotensin inhibitors, and vasodilators.<sup>6</sup> The later, together with  $\text{Ca}^{2+}$  antagonists and angiotensin inhibitors, is becoming wider and earlier choice as first or second line of drugs to control blood pressure.<sup>5</sup>

We have discovered a group of compounds that potently relax vascular and bronchial smooth muscles, therefore, have great potential to be developed into new therapeutic agents to treat hypertension and hypertension-related heart diseases and stroke as well as spasmodic asthma.

The prototype of the compounds was synthesized two decades ago,<sup>7</sup> when searching for better local anesthetic and antiarrhythmic agents. One of the original compounds, [2-(diethylamino)acetamido]-3-carbamyl-4-methyl-5-benzylpyrrole (Structure I) was reported to decrease blood pressure.<sup>8-9</sup> The therapeutic use of the benzyl compound was ruled out due to its low water solubility and its propensity to precipitate in blood.


With the availability of state-of-the art techniques and instruments for studying the mechanism of action of cardiovascular agents, we have recently evaluated the effects of [2-(diethylamino)acetamido]-3-carbamyl-4-methyl-5-methylthioethylpyrrole (Structure II) on smooth muscle contraction and on blood pressure. We discovered that this soluble compound markedly relaxed high potassium-caused smooth muscle contracture *in vitro* and lowered the blood pressure *in vivo*. By modifying the chemical structure, we defined a new group of chemical compounds that, like the prototype compound II, could have immense therapeutic value in treatment of cardiovascular disorders.



Compound	R
I	$-\text{CH}_2-\text{C}_6\text{H}_5$
II	$-\text{CH}_2\text{CH}_2\text{SCH}_3$



The general structure for our invention disclosure is given below. The R groups are inclusively defined, respectively.



where,

$R_1 = \text{CH}_3, \text{CH}_2\text{CH}_3, \text{CONH}_2, \text{CH}_2\text{SCH}_3, \text{CH}_2\text{SCH}_2\text{CH}_3, \text{CH}_2\text{CH}_2\text{SCH}_3, \text{CH}_2\text{CH}_2\text{SCH}_2\text{CH}_3, \text{CH}_2\text{NCH}_3, \text{CH}_2\text{NCH}_2\text{CH}_3$ , or the R group of any naturally occurring  $\alpha$ -amino acid;

$R_2 = \text{H}, \text{CH}_3, \text{CH}_2\text{CH}_3, \text{CH}_2\text{SCH}_3, \text{CH}_2\text{SCH}_2\text{CH}_3, \text{CH}_2\text{CH}_2\text{SCH}_3$ , or  $\text{CH}_2\text{CH}_2\text{SCH}_2\text{CH}_3$ ;

$R_3 = \text{CH}_3, \text{C}_2\text{H}_5, \eta\text{C}_3\text{H}_7, \iota\text{C}_3\text{H}_7$ , or  $\eta\text{C}_4\text{H}_9$ ;

$R_4 = \text{CH}_3, \text{C}_2\text{H}_5, \eta\text{C}_3\text{H}_7, \iota\text{C}_3\text{H}_7$ , or  $\eta\text{C}_4\text{H}_9$ .

## Biological Evaluation

### I. Smooth muscle relaxation

#### A. In vitro vascular smooth muscle responses:

The prototype of the compounds (compound II) was tested for activity to relax vascular smooth muscles using abdominal aorta and vein preparations from Sprague-Dawley rats and Sus-Scrota pigs. The rat vessels were obtained immediately after the animal was sacrificed for another research project (Animal protocol # 1091, approved by IACUC of USC) and the porcine tissues were obtained within 30 min after the pig was sacrificed at the end of an Advanced Trauma Life Support Course (a training course organized by the College of Medicine and Animal Facility of USC). The vessels were cleaned of adherent fat and connective tissue and then cut into 3~5-mm ring segments. The segments were cut longitudinally into arterial strips without removal of the endothelium.

The strips were tied to the extremities by two silk threads and vertically mounted in a water-jacketed tissue bath, maintained at 37 °C, between moveable and fixed ends of a stainless steel wire with the moveable end attached to a TRI 201 isometric transducer (LSi LETICA Scientific Instruments) that was coupled to a bridge amplifier (PowerLab, ADInstruments) for recording isometric force responses. The data were digitized through a 16 SP interface and acquired on-line with Chart 4.0 software (PowerLab, ADInstruments) and stored to a personal computer.

The bath was filled with 30 ml of oxygenated (95% O<sub>2</sub> and 5% CO<sub>2</sub>) Kreb's solution containing (in mM): 135 NaCl, 15 NaHCO<sub>3</sub>, 5.4 KCl, 1.2NaH<sub>2</sub>PO<sub>4</sub>, 1.2 MgSO<sub>4</sub>, 1.8 CaCl<sub>2</sub>, and 10 glucose. The strips were equilibrated for at least 30 min before approximately 0.3 gram (for rat tissues) or 1 gram (for pig tissues) of passive tension was placed on them. Thereafter, contracture (static muscle shortening) was produced with potassium chloride by substituting 64.6 mM KCl for the same

amount of NaCl in the Krebs solution (i.e., final concentration of  $K^+$  = 70 mM). When the potassium-induced contracture reached a stable plateau level, various concentrations of the testing compound were added to the bath solution to record the concentration-response curve. Each concentration of the compound was allowed to elicit its maximal relaxation. In most of the experiments, the higher concentration was reached by accumulatively adding the agent to the bath solution. The relaxation response produced by the compound was normalized to the response produced by 10  $\mu$ M nitroglycerin added to the bath solution at the end of the experiment. Figure 1 shows the typical vascular relaxation effects produced by the prototype of the compounds on porcine arterial (panel *a*) and vein (panel *b*) strips. Similar results were observed in rat tissues (not shown).

#### B. In vitro bronchial smooth muscle responses:

The compound II was also tested for activity to relax bronchial smooth muscles using the main bronchia from Sprague-Dawley rats. The rat bronchial tissues were obtained immediately after the rat was sacrificed for another research project (Animal protocol # 1091, approved by IACUC of USC). Both the right and left main bronchi were cleaned of adherent fat and connective tissue and trimmed into ~3 mm ring segments, which were cut longitudinally at the circumference of the hyaline cartilage without removal of the endothelium. The strips, with the membranous wall (a fibrous membrane containing smooth muscular fibers) in the middle, were tied to the extremities (cartilage+annular ligament) by two silk threads and vertically mounted in a water-jacketed 37 °C tissue bath. The experimental protocol and data acquisition were same as that used for rat vascular smooth muscles (see above). Figure 2 shows the typical bronchial relaxation responses produced by the prototype of the compounds.

### II. In vivo blood pressure reduction effects

#### A. Intravenous bolus injection of the compound II on blood pressure:

Female Sprague-Dawley rats weighing 200-225 grams were anesthetized with pentobarbital (30 mg/kg body weight, i.p.). The animal was positioned supinely on a heat plate that was controlled by an automatic temperature controller system (TC-324B, Warner Instrument Corp.) to maintain its body temperature constant (36 $\pm$ 0.5°C) during the experiment. The trachea, right carotid artery, and left femoral vein were exposed. The trachea was cannulated and the animal was breathed with air through a respirator at a rate of 65-70/min and an inspiration pressure of ~10 cm H<sub>2</sub>O. PE catheters were implanted into the carotid artery and femoral vein, respectively. The animal was heparinized by i.v. injection of ~300 units of heparin dissolved in 0.3 ml of 0.9% saline. Arterial pressure was recorded from the carotid artery catheter connected to a physiological pressure transducer (SP 844, Capto company, Norway) that was coupled to a bridge amplifier (PowerLab, ADInstruments). The data were digitized through a 16 SP interface and acquired on-line with Chart 4.0 software (PowerLab, ADInstruments) and stored to a personal computer.

After surgery, the animal was allowed to equilibrate for ~30 minutes before administration of the test compounds. The experiments in which the control carotid pulse pressure (difference between the systolic and diastolic pressure) was less than 30 mmHg were discarded without testing the drug's effects. Various doses (0.1-4 mg/kg.bw) of the test agents dissolved in 0.9% saline were administered as boluses through the femoral vein cannula in volumes ranging from 0.25-0.3 ml. Same volume of saline was used to flush the injection line following each administration of drug. Each dose of the compound was allowed to elicit its maximal effects. The changes in systolic, diastolic, and mean pressure (calculated as diastolic pressure+1/3 pulse pressure) caused by the test agents were compared to that measured at the end of the 30 min equilibration. During the experimental period, ECG was simultaneously recorded with a Bio Amplifier (PowerLab, ADInstruments) through two electrodes placed on the right and left forearms to monitor the possible effect of the test agents on heart rate. Figure 3 shows the representative responses of blood pressure and heart rate after bolus injection of the

compound II (note: the data shown in figure 3 were from the same rat. The lower mean blood pressure (MBP) and heart rate at the beginning of recordings in Panel C were due to application of verapamil and nitroglycerin before lidocaine injection).

B. Oral administration of the compound II on blood pressure:

The compound II was administered to two female rats via oral gavage at a dose of 26 and 80 mg/kg.bw, respectively. The agent was dissolved in 0.9% saline in a volume of 0.5 ml. Same volume of saline alone was administered to two control animals. After 15 minutes, the animal was anesthetized with pentobarbital (30 mg/kg.bw, i.p.) and same surgery was performed except that the femoral vein was not exposed and there was no i.v. administration of the test agent. The carotid blood pressure and heart rate were monitored and recorded for 60 minutes using the same method described above. The initial recording was made within 45 to 65 minutes after performing oral gavage. The results are reported in the following Table (the MBP and HR were measured within 30 min after the surgery).

	Oral Gavage Compound II on Blood Pressure and Heart Rate		
	Saline	Compound II	
		26 mg/kg.bw	80 mg/kg.bw
MBP (mm Hg)	186	156	126
HR (Beet/min)	364	384	300

Also embraced within this invention is a class of pharmaceutical agents including one or more compounds of the formula structure in association with one or more non-toxic, pharmaceutically acceptable carrier materials such as diluents and adjuvants or other active/inactive ingredients. The invention covers all suitable and therapeutically effective administration routes, such as administered intravascularly, intraperitoneally, subcutaneously, intramuscularly, or topically.

Reference

1. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1997; 157:2413
2. Andersson OK, et al. Survival in treated hypertension: Follow up study after two decades. BJM 1998; 317:167-171
3. Woodwell DA: National Ambulatory Medical Care Survey: 1997 Summary. Advance Data from Vital and Health Statistics. 1999, National Center for Health Statistics. Hyattsville, MD; No. 305
4. MacMahon S, et al. Blood pressure and coronary heart disease: Part 1, prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335:765
5. Braunwald E, Zipes DP, Libby P. Heart Disease. A textbook of cardiovascular medicine. (6<sup>th</sup> ed) W.B. Saunders Company. 2001; Vol 1, pp 972-995
6. Oates JA and Brown NJ. Antihypertensive agents and the drug therapy of hypertension. In Goodman & Gilman's The Pharmacological Basis of Therapeutics (10<sup>th</sup> Ed). Publisher: McGraw Hill; 2001; Chapter 33, pp 871-900
7. Johnson RW, et al. Synthesis of substituted 2-aminopyrrole analogs of lidocaine II. J. Pharmaceut. Sci. 1979; 68:955-958

8. Keenan TH, et al. Selected cardiovascular and central properties of three lidocaine analogs. *Pharmacology* 1979; 19:36-43
9. Chiang YL, et al. Benzyl carbamyl analogue of lignocaine: vasodepressor mechanism of action. *Clin. Exp. Pharmacol. Physiol.* 1982; 9:645-655




Figure 1. Prototype compound-produced relaxation of vascular smooth muscle. Panel a. rat abdominal arterial strip was statically shortened by 70 mM KCl indicated by the arrow. The test compound was added accumulatively at the concentration as indicated by the numbers. NG=10  $\mu$ M nitroglycerin. Panel b. similar experiment as in Panel a, except that porcine vein strip was used.




Figure 2. The prototype compound-produced relaxation of rat bronchial strip that was statically shortened by 70 mM KCl as indicated by the arrow. The bars and numbers indicate the application time and concentrations of the agent, respectively.




Figure 3. Effects of the prototype compound on rat carotid blood pressure and heart rate when administered intravenously (bolus injection, Panel a and b). Lidocaine's effects were included for comparison (Panel c).

**From:** "Wang, Desuo" <Wang@cop.sc.edu>  
**To:** "Mike Muthig" <Muthigm@gwm.sc.edu>  
**Date:** 4/24/03 5:20PM  
**Subject:** RE: Wang, 341 Provisional patent application

Mike,  
Here is the update of 341 summary. The research is still going on. So there will be more data in the future.  
Thanks.

Desuo

—Original Message—

**From:** Mike Muthig [mailto:Muthigm@gwm.sc.edu]  
**Sent:** Tuesday, April 22, 2003 2:00 PM  
**To:** Wang, Desuo  
**Subject:** Wang, 341 Provisional patent application

Thank you for meeting this morning to review the provisional patent application, which expires on May 31, 2003. As discussed, given the absences of a publication, new information that has been developed, and limited interest resulting from marketing efforts, the provisional patent application will be allowed to expire.

A new provisional patent application will be prepared that will include the following information:

Information included in the original application;  
Information that was developed since the original submittal;  
Information to be presented in your students defense;  
Any other information that you would like to have included at this time.

Please forward any information that you would like to have included in the new application. I would like to submit the application prior to your students defense. I need at least 24 hours to prepare the application for submittal.

Please feel free to call if you have questions or comments.

Regards,

Micheal

\*\*\*\*\*

Michael Muthig, Ph.D.  
Senior Licensing Officer  
USC Research Foundation  
901 Sumter Street, 5th Floor  
Columbia, SC 29208

Phone: 803-777-4031  
Fax: 803-777-4136  
mgm@sc.edu



# Novel Synthetic Antihypertensive and Antiasthmatic cAMP-specific Phosphodiesterase Inhibitors

**General:** the compounds are chemically synthesized and have a high yield. They are fairly soluble in acidic solution (~30 mg/ml, pH=3), light and heat stable, bioavailable *via* oral gavage, with a reasonable partition coefficient (i.e., with a calculated Logp value of 1.79), relatively low toxicity, reliable efficacy, and acceptable potency.

## Preliminary Experimental Data

### A. Effect on Blood Pressure

1. In anesthetized rats (SD, SHR, and Zucker (*fa/fa*)), administration of the compounds, *via* oral gavage (10 mg/kg.body weight), intravenous bolus injection (1 mg/kg.body weight), or continuous intravenous infusion (at a rate of 30 µg/kg.min for 10 min), significantly lowered the systolic and diastolic blood pressure measured from carotid artery.
2. In awake animals (SD, SHR, and Zucker (*fa/fa*) rats), administration of the compounds, *via* oral gavage (20 mg/kg.body weight) or intraperitoneal injection (1 mg/kg.body weight), also significantly lowered blood pressure measured with non-invasive tail-cuff method.
3. In anesthetized dogs, intravenous bolus injection of the prototypic compound at a dose of 0.25 mg/kg.bw produced a 4 mmHg decrease in blood pressure. Higher doses produced greater decrease in blood pressure.

	HR	BP Max	BP Min	BP Mean	LVSP	LVEDP
Control	119.8	99.8	46.6	67.2	78.5	8.7
Bolus 1 mg/kg.bw	118.2	90.5	39.8	58.4	71.8	9.0
Bolus 2 mg/kg.bw	109.7	76.8	33.7	48.0	63.1	9.2

HR, heart rate; BP, blood pressure; BP Max, maximum systolic pressure;  
BP Min, minimum diastolic pressure; LVSP, left ventricular systolic pressure;  
LVEDP, left ventricular end diastolic pressure.


### B. Effects on Heart Rate and Cardiac Contractility

1. *in vivo* studies in anesthetized or awake rats, the compounds did not produce obvious negative chronotropic effect when administered *via* oral gavage or intraperitoneal injection or intravenous infusion. The heart rate was markedly decreased when a bolus injection was applied to anesthetized rats.
2. In Langendorff-perfused rat hearts, the compounds (30 µM) did not affect the heart beating rate and left ventricular contractility measured as left ventricular developing pressure (LVDP) using balloon method.
3. The effects of the compounds on atrium beating rate and contraction were also studied using tissue bath method. After the beating of the right atrium of

guinea pig was initiated and maintained at a constant rate by  $\beta$ -adrenergic agonist isoproterenol (200-500 nM), the compounds (30  $\mu$ M) did not affect the positive chronotropic and inotropic responses of the atrium to isoproterenol stimulation. This is different from other phosphodiesterase inhibitors, such as 10  $\mu$ M milrinone or 10  $\mu$ M rolipram that markedly enhanced the positive chronotropic and inotropic effects of isoproterenol.

### C. Relaxation Effects on the Blood Vessel Rings

1. *In vitro* experiments, the compounds fully relaxed high  $K^+$ -contracted (35, 70, or 140 mM) aorta rings of rats and guinea pigs. The relaxation was also effective when tested in intra-renal and coronary arterial rings (1~2 mm) as well as pig main kidney arterial and venous rings. The vasodilatation responses were endothelium independent, reversible upon washout, and lack of desensitization. The effects were not affected by elevating extracellular  $K^+$  concentration from 70 mM to 140 mM. The efficacy and potency were similar in arterial and venous vessels, with a  $K_d$  value of approximate 15  $\mu$ M.




MS23 relaxes high  $K^+$  caused-contraction of porcine kidney artery ring.

2. The compounds also relaxed norepinephrine or phenylephrine-caused vessel constriction.
3. The relaxation action on 70 mM  $K^+$ - or norepinephrine-induced contraction was not affected in the presence of indomethacin (cyclooxygenase inhibitor), U73122 (PLC inhibitor), BQ-123 ( $ET_A$  antagonist), BQ-788 ( $ET_B$  antagonist), or CGS 15943 ( $A_1$  and  $A_2$  antagonist).

### D. Relaxation Effects on Airway Smooth Muscles


1. The compounds fully relaxed high  $K^+$ -caused contraction of rat tracheal and bronchial rings ( $K_d=10 \mu$ M). The action was epithelial-independent. And the relaxation effect was not affected in the presence of the listed antagonists or inhibitors:

- 1) histamine H<sub>2</sub> receptor antagonist ranitidine (10-100  $\mu$ M),
  - 2) adenosine A<sub>1</sub> and A<sub>2</sub> receptor antagonist CGS 15943 (10 nM),
  - 3) non-selective  $\beta$ -adrenergic receptor antagonist propranolol (1-5  $\mu$ M) and selective  $\beta_2$  and  $\beta_3$  antagonists ICI 118511 (10  $\mu$ M), SR59230A (5-10  $\mu$ M), respectively, or  $\alpha_1$ -adrenergic receptor antagonist prazosin (1  $\mu$ M).
  - 4) phospholipase C (PLC) inhibitor U73122 (3-10  $\mu$ M),
  - 5) cyclooxygenase (COX-1) inhibitor indomethacin (1-10  $\mu$ M),
  - 6) intracellular Ca<sup>2+</sup>-release inhibitor ryanodine (10  $\mu$ M),
  - 7) adenylyl cyclase inhibitor 2'5'-dideoxyadenosine (30  $\mu$ M),
  - 8) nitric oxide synthase inhibitor Nitro-L-Arginine Methyl Ester (L-NAME, 100  $\mu$ M),
  - 9) non-selective PKC inhibitor staurosporin (1  $\mu$ M),
  - 10) T-type Ca<sup>2+</sup> channel blocker Ni<sup>2+</sup> (0.1-1 mM),
  - 11) large-conductance (BK) Ca<sup>2+</sup>-activated K<sup>+</sup> channel blocker TEA<sup>+</sup> (2 mM).
2. The compounds also relaxed histamine (100  $\mu$ M)-caused contraction of guinea pig trachea and bronchi.
3. Although the compounds do not relaxed the maximal contraction induced by carbachol (10  $\mu$ M) (only to ~10% of the maximal relaxation of atropine) in guinea pig airway smooth muscles, they markedly enhanced isoproterenol produced relaxation. The compounds caused a leftward displacement by at least one log unit of the concentration-response curve of isoproterenol-produced relaxation in airway rings contracted by carbachol (10  $\mu$ M) and the relaxing efficacy increased from 30% to 45% of the maximal relaxation of atropine.



Concentration- response curve of isoproterenol-induced relaxation of rat bronchi rings contracted with 10 $\mu$ M carbachol in the absence and presence of 10 $\mu$ M MS23 (a concentration itself does not have relaxation effect on 10  $\mu$ M CCh-caused contraction). MS23 increases the potency and efficacy of isoproterenol induced bronchodilation. Open circle: ISO+MS23; closed dot: ISO alone.

4. Pre-relaxation of 10  $\mu\text{M}$  carbachol-caused airway contraction with forskolin (10  $\mu\text{M}$ ) significantly potentiated the compounds' relaxation effect. However, relaxation of carbachol-caused contraction by ROCK inhibitor, Y27632 (10  $\mu\text{M}$ , selectively inhibiting the rho-associated coiled coil-forming protein kinase-ROCK) did not potentiate the compounds' action.




A. Carbachol-caused contraction of rat bronchial rings can not be relaxed by MS23 alone. B. In the presence of Forskolin, MS23 relaxes carbachol-caused contraction. C. Y27632 Does not potentiate MS23's action. (CCh: carbachol; Forskolin, adenylyl cyclase activator. Y27632, ROCK)

5. In  $\beta$ -escin (100  $\mu\text{M}$ ) permeated tracheal smooth muscles, when free  $\text{Ca}^{2+}$  was buffered to 50  $\mu\text{M}$  with BAPTA and ATP, the compounds relaxed calmodulin (10,000 units)-induced contraction.
6. In comparison to isoproterenol (1-3  $\mu\text{M}$ ) or calcium channel blocker (combination of 2  $\mu\text{M}$  nifedipine and 5  $\mu\text{M}$  verapamil), the prototypic compound (30  $\mu\text{M}$ ) significantly attenuated the efficacy of  $\text{Ca}^{2+}$ -induced contraction, when rat airway rings were depolarized with 70 mM  $\text{K}^+$ .


### E. Vasodilator-stimulated Phosphoprotein (VASP) Assay

Vasodilator-stimulated phosphoprotein (VASP) is an actin filaments-associated protein that serves as a substrate for cAMP and cGMP-dependent protein kinases. Western blot carried out with phosphorylation-specific antibodies for VASP demonstrated that the 50 kD phosphorylated form of VASP was markedly increased in rat tracheal smooth muscle by the prototypic compound treatment for 30 min at a concentration of 100  $\mu\text{M}$  (a concentration that can fully relax 70 mM  $\text{K}^+$ -caused contraction).



## F. Phosphodiesterase (PDE) Assay

The prototypic compound concentration-dependently inhibited the total activity of cAMP phosphodiesterases (PDEs) contained in the protein extract from brain tissue and airway smooth muscles.



Inhibition of phosphodiesterase activity by MS23 measured as the ratio of conversion of cAMP to 5'-AMP using  $^3\text{H}$ -cAMP radioisotope scintillation.

## G. Other Results

1. The compounds (100  $\mu$ M) failed to stimulate cAMP production in rat adipose cells.
2. The compounds (100  $\mu$ M) did not relax high  $\text{K}^+$ -caused contraction of pig ureteral or guinea pig intestine (ileum and duodenum) rings that could be fully relaxed by 10  $\mu$ M salbutamol (a selective  $\beta_2$ -adrenergic receptor agonist) or combination of verapamil (5  $\mu$ M) and nifedipine (2  $\mu$ M) or milrinone (a PDE3-selective inhibitor).
3. Patch-clamp recordings showed that the compound did not cause changes in action potential duration and amplitude in both rat and guinea pig ventricular myocytes. The compounds also did not change resting membrane potential. In contrast, PDE inhibitor milrinone (10  $\mu$ M) significantly prolonged action potential duration of guinea pig ventricular myocytes.
4. There were no observed adverse effects in 6 Zucker (*fa/fa*) rats that continuously received a single daily dose (40-60 mg/kg.body weight) of the prototypic compound *via* oral gavage for three weeks. The compounds were non-emetic in the rats at a dose range of 20-80 mg/kg.bw (oral gavage).

## Potential Areas of Use

1. Treatment of cardiovascular conditions (including systemic hypertension, angina pectoris, hypertension-related stroke and heart failure).
2. Treatment of asthma: as a monotherapy or as an adjunct therapy to enhance the therapeutic effect of the existing  $\beta$ -adrenergic agonists in asthma treatment, and reduce the dose, therefore, the adverse effect of the current used agents.

## **Main Advantages**

1. Fast action (response occurs within 30 min after oral gavage, <3 min after intraperitoneally, immediate after intravenously).
2. Less adverse effects (less action on heart rate and myocardium contraction; mild action; no hypotensive-caused reflex reaction, no emetic reaction) and low toxicity.
3. No desensitization.
4. Effects are reversible and reproducible.
5. Relatively selective in action on airway and vascular smooth muscles.
6. Similar potency and efficacy in arteries and veins.
7. Significantly improvement in solubility
8. Reduced therapy cost.

## **Chemistry**

1. The structure and purity (organic) have been verified by NMR ( $H^+$  and  $C^{13}$ ) measurements (>99.9% purity).
2. The structure and molecular weight have been confirmed using high resolution mass spectrometry (<0.02% of discrepancy from calculated molecular weight).

**The preliminary data indicates that the compounds may selectively relax airway and vascular smooth muscles by inhibiting a subtype 4 cAMP-specific phosphodiesterase.**

## The antihypertensive activity of a new vasodilator MS23

**Background:** 2-[2-(N-ethyl-N-n-propyl) amino] propionamido-3-carbamyl-4-methyl-5-(methylthioethyl) pyrrole (MS23) is a new synthetic vasodilator, which selectively inhibits the enzymatic activity of cyclic AMP specific phosphodiesterase to cause the relaxation of vascular and air way smooth muscles. This study is to evaluate the antihypertensive effect and the potential action of MS23 on heart rate and cardiac contraction using *in vivo* and *ex vivo* models. **Method and results:** 1. In anesthetized SHR and SD rats, MS23 intravenous bolus injection at a dose of 0.5 mg/kg body-weight resulted in a decrease in the mean blood pressure (measured at carotid artery) by -15.6 mmHg (-16.1 and -15.4 mmHg for systolic and diastolic pressure, respectively), and by -45.8 mmHg (-45.2 and -46.1 mmHg for systolic and diastolic pressure, respectively) at a dose of 4 mg/kg body weight. The decrease in BP occurred immediately after MS23 administration and lasted for 3 to 6 min dependent on the dose. In anesthetized dogs, intravenous bolus injection of MS23 at a dose of 0.25 mg/kg produced a 4 mmHg decrease in blood pressure and higher dose produced greater decrease in blood pressure. 2. Continuous intravenous infusion of MS23 at a speed of 1.85  $\mu$ g/min produced a steady-state reduction of the MBP by -28.3 mmHg (systolic -27.2 and diastolic -28.9 mmHg). 3. In awake SHR and SD rats, administration of MS23 via oral gavage (40 mg/kg body-weight) or intraperitoneal injection (20 mg/kg body-weight) also significantly lowered MBP (measured with non-invasive tail-cuff method) by -18.4 mmHg (systolic -20.3 and diastolic -17.4 mmHg) and -35.2 mmHg (systolic -35.4 diastolic -35.1 mmHg), respectively. 4. In anesthetized animals, high dose of MS23 (>2 mg/kg body-weight) produced a negative chronotropic effect when via intravenously administrated (bolus). The average decrease in heart rate was ~15 beat/min. The negative chronotropic effect was not observed when MS23 was administrated via oral gavage (40 mg/kg.bw), intraperitoneal injection (20 mg/kg.bw) or intravenous infusion (30  $\mu$ g/kg.bw). 5. In Langendorff-perfused rat hearts, MS23 (30  $\mu$ M) did not affect the heart rate and left ventricular contractility measured as left ventricular developing pressure (LVDP) via a balloon inserted in the left ventricle. **Conclusion:** MS23 potently and non-preferably reduces both systolic and diastolic blood pressure with negligible action on heart rate and cardiac contractility.

## **The Electrophysiological Effects of a Novel cAMP Specific Phosphodiesterase Inhibitor MS23 in Isolated Guinea Pig Cardiomyocytes**

An Xie, Ting Wang and Desuo Wang  
Department of Basic Pharmaceutical Sciences, College of Pharmacy,  
University of South Carolina, Columbia, SC 29208, USA

The effects of a novel synthesized cAMP specific phosphodiesterase inhibitor MS23 on action potential parameters were examined and compared with those of milrinone (10  $\mu\text{mol/l}$ , a PDE III inhibitor) and rolipram (30  $\mu\text{mol/l}$ , a selective PDE IV inhibitor) in isolated guinea-pig atrial and ventricular myocytes. Action potentials (AP) were recorded under nystatin-perforated whole-cell patch-clamp configuration at a temperature of  $35\pm0.5^\circ\text{C}$ . MS23 at a concentration of 30  $\mu\text{M}$  significantly shortened  $\text{APD}_{90}$  (action potential duration measured at 90% of repolarization) from  $304.9\pm24.0$  msec to  $254.9\pm28.4$  msec ( $P<0.05$ ,  $n=8$ ) in ventricular cells but had no effect on APD in atrial cells. MS23 did not affect the amplitude, resting membrane potential, and the rate of depolarization. MS23 did not prolong APD at concentrations range from 1 to 100  $\mu\text{M}$ . In comparison, rolipram (30  $\mu\text{M}$ ) also shortened  $\text{APD}_{90}$  from  $318.3\pm8.9$  msec to  $274.6\pm9.8$  msec ( $P<0.05$ ,  $n=3$ ) in ventricular cells but consistently showed a small but notable delay of phase 1 and plateau phase but acceleration of phase 3 repolarization. In contrast, milrinone (10  $\mu\text{M}$ ) elongated ventricular  $\text{APD}_{90}$  from  $287.9\pm10.3$  msec to  $327.8\pm17.4$  msec ( $P<0.05$ ,  $n=4$ ). Nevertheless, after treatment of ventricular cells with either rolipram or MS23, milrinone (10  $\mu\text{M}$ ) markedly shortened  $\text{APD}_{90}$  recorded from the same cells. In atrial cells, milrinone caused a greater delay of phase 1 and plateau phase but acceleration of phase 3 repolarization ( $\text{APD}_{90}$  shortened from  $153.9\pm12.1$  msec to  $135.5\pm12.3$  msec,  $P<0.05$ ,  $n=4$ ). The results indicate that MS23 may have a different PDE inhibition spectrum from rolipram and milrinone. The PDE sensitive to MS23 may exclusively expressed in ventricular myocardium.



## Investigation of MS23 induced smooth muscle relaxation

We investigated the smooth muscle relaxation action of 2-[2-(N-ethyl-N-n-propyl) amino] propionamido-3-carbamyl-4-methyl-5-(methylthioethyl) pyrrole (MS23), a novel synthetic antihypertensive and antiasmatic reagent. MS23 relaxed 70mM KCl contracted blood vessel and airway smooth muscle rings from rat and guinea pig, in a concentration-dependent manner, with an  $EC_{50}$  value of approximate 10  $\mu$ M. The effects were endothelium independent. MS23 also relaxed norepinephrine/phenylephrine caused vessel contraction and histamine (100 $\mu$ M) contracted guinea pig trachea and bronchi. MS23 showed different tissue specificity against L-type  $Ca^{2+}$  channel blockers nifedipine (2 $\mu$ M) and Verapamil (5 $\mu$ M). In carbachol (10 $\mu$ M) contracted guinea pig smooth muscle rings (trachea and bronchi), pretreatment of MS23 (10 $\mu$ M, at which MS23 relaxed less than 10% of the maximal relaxation by atropine) potentiated the relaxation induced by isoproterenol (0.01-10 $\mu$ M) significantly. Moreover, forskolin (10 $\mu$ M, adenylyl cyclase activator) potentiated MS23 (30 $\mu$ M) induced relaxation significantly (5 folds), which indicated the interference of MS23 in the signaling of cyclic AMP induced smooth muscle relaxation. The enzymatic activity measurement of phosphodiesterases (PDE, sample from guinea pig brain protein extract) which converted cAMP to 5'-AMP showed that MS23 inhibited PDE activity concentration dependently. Conclusion: MS23 relaxed smooth muscle tissue by the inhibition of cyclic AMP specific phosphodiesterase.

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US04/037813

International filing date: 12 November 2004 (12.11.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US  
Number: 60/519,140  
Filing date: 12 November 2003 (12.11.2003)

Date of receipt at the International Bureau: 05 January 2005 (05.01.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

**This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record.**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:



☒ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**



☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**



☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**